Prognostic role of preimplantation genetic testing for aneuploidy in medically indicated fertility preservation

To investigate the use of preimplantation genetic testing for aneuploidy (PGT-A) among patients pursuing embryo banking (EB) for medically indicated fertility preservation (FP). Retrospective cohort. University-affiliated fertility center. All patients who underwent in vitro fertilization with or wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Fertility and sterility 2020-02, Vol.113 (2), p.408-416
Hauptverfasser: Blakemore, Jennifer K., Trawick, Emma C., Grifo, James A., Goldman, Kara N.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:To investigate the use of preimplantation genetic testing for aneuploidy (PGT-A) among patients pursuing embryo banking (EB) for medically indicated fertility preservation (FP). Retrospective cohort. University-affiliated fertility center. All patients who underwent in vitro fertilization with or without PGT-A for medically indicated FP between January 2014 and April 2018. None EB cycle characteristics, subsequent cycle pursuit/outcomes, and frozen embryo transfer (FET) outcomes. A total of 58 medical EB cycles were compared; 34 cycles used PGT-A. Of the EB patients with breast cancer, 67% used PGT-A; other indications were evenly divided between PGT-A (FP/PGT-A) and no PGT-A (FP). PGT-A use increased over the study period. Groups were similar in age, days of stimulation, and days from initial FP consultation to treatment initiation. Number of oocytes (14.5 [2−63] FP vs. 17.5 [1−64] FP/PGT-A), 2PN zygotes (7 [1−38] FP vs. 9 [0−36] FP/PGT-A), and blastocysts (5.5 [0−22] FP vs. 5 [0−18] FP/PGT-A) cryopreserved were similar between groups. Equal numbers cryopreserved both oocytes and embryos (5 vs. 3). Five FP/PGT-A patients underwent a second EB cycle. Among FP/PGT-A patients, an average of 6.7 ± 5 blastocysts underwent PGT-A, with 3.5 ± 3 (48.2%) euploid embryos cryopreserved for future FET compared to an average of 7.2 ± 7 untested embryos in the FP group. PGT-A in medical EB cycles increased over time and did not limit the use of other FP methods such as oocyte cryopreservation. In some cases, poor PGT-A results informed patients to pursue a second EB cycle. When counseling patients, the prognostic benefits of PGT-A must be weighed against the financial costs and potential for “terminal” fertility diagnosis. Papel pronóstico del estudio genético preimplantacional de aneuploidías en la preservación de la fertilidad por indicación médica Investigar el uso del estudio genético preimplantacional de aneuploidías (PGT-A) en pacientes encaminadas a congelación embrionaria (EB) para preservación de la fertilidad por indicación médica. Cohorte retrospectiva. Centro de fertilidad afiliado a la universidad. Todas las pacientes que realizaron fecundación in vitro con o sin PGT-A para preservación de la fertilidad por indicación médica entre enero de 2014 y abril de 2018. Ninguna. Características de los ciclos de EB, subsecuente búsqueda de otro intento/resultados, y resultados de las transferencias de embriones congelados. Se compararon un total de 58 ciclos EB por i
ISSN:0015-0282
1556-5653
DOI:10.1016/j.fertnstert.2019.09.040